Literature DB >> 32953622

The Peony trial: adding evidence to pertuzumab use in non-metastatic breast cancer.

Tomas Cortadellas1, Xavier Gonzàlez-Farré1.   

Abstract

Entities:  

Year:  2020        PMID： 32953622      PMCID： PMC7475362          DOI： 10.21037/gs.2020.03.11

Source DB:  PubMed          Journal:  Gland Surg        ISSN： 2227-684X


× No keyword cloud information.
  16 in total

1.  Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Sara M Tolaney; Hao Guo; Sonia Pernas; William T Barry; Deborah A Dillon; Lauren Ritterhouse; Bryan P Schneider; Fei Shen; Kit Fuhrman; Michele Baltay; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Mathew J Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth Overmoyer; Ann H Partridge; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  J Clin Oncol       Date:  2019-04-02       Impact factor: 44.544

2.  Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.

Authors:  Heikki Joensuu; Judith Fraser; Hans Wildiers; Riikka Huovinen; Päivi Auvinen; Meri Utriainen; Paul Nyandoto; Kenneth K Villman; Päivi Halonen; Helena Granstam-Björneklett; Lotta Lundgren; Liisa Sailas; Taina Turpeenniemi-Hujanen; Minna Tanner; Jeffrey Yachnin; Diana Ritchie; Oskar Johansson; Teppo Huttunen; Patrick Neven; Peter Canney; Vernon J Harvey; Pirkko-Liisa Kellokumpu-Lehtinen; Henrik Lindman
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

3.  Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.

Authors:  P Conte; A Frassoldati; G Bisagni; A A Brandes; M Donadio; O Garrone; F Piacentini; L Cavanna; F Giotta; M Aieta; V Gebbia; A Molino; A Musolino; A Ferro; R Maltoni; S Danese; C Zamagni; A Rimanti; K Cagossi; A Russo; P Pronzato; F Giovanardi; G Moretti; L Lombardo; A Schirone; A Beano; L Amaducci; E A Bajardi; R Vicini; S Balduzzi; R D'Amico; V Guarneri
Journal:  Ann Oncol       Date:  2018-12-01       Impact factor: 32.976

4.  6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial.

Authors:  Xavier Pivot; Gilles Romieu; Marc Debled; Jean-Yves Pierga; Pierre Kerbrat; Thomas Bachelot; Alain Lortholary; Marc Espié; Pierre Fumoleau; Daniel Serin; Jean-Philippe Jacquin; Christelle Jouannaud; Maria Rios; Sophie Abadie-Lacourtoisie; Laurence Venat-Bouvet; Laurent Cany; Stéphanie Catala; David Khayat; Laetitia Gambotti; Iris Pauporté; Celine Faure-Mercier; Sophie Paget-Bailly; Julie Henriques; Jean Marie Grouin
Journal:  Lancet       Date:  2019-06-06       Impact factor: 79.321

5.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

6.  HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.

Authors:  Antonio Llombart-Cussac; Javier Cortés; Laia Paré; Patricia Galván; Begoña Bermejo; Noelia Martínez; Maria Vidal; Sònia Pernas; Rafael López; Montserrat Muñoz; Paolo Nuciforo; Serafín Morales; Mafalda Oliveira; Lorena de la Peña; Alexandra Peláez; Aleix Prat
Journal:  Lancet Oncol       Date:  2017-02-24       Impact factor: 41.316

Review 7.  Emerging evidence for the role of differential tumor microenvironment in breast cancer racial disparity: a closer look at the surroundings.

Authors:  Sachin Kumar Deshmukh; Sanjeev K Srivastava; Nikhil Tyagi; Aamir Ahmad; Ajay P Singh; Ahmed A L Ghadhban; Donna L Dyess; James E Carter; Kari Dugger; Seema Singh
Journal:  Carcinogenesis       Date:  2017-08-01       Impact factor: 4.944

Review 8.  Breast cancer in China.

Authors:  Lei Fan; Kathrin Strasser-Weippl; Jun-Jie Li; Jessica St Louis; Dianne M Finkelstein; Ke-Da Yu; Wan-Qing Chen; Zhi-Ming Shao; Paul E Goss
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

9.  Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.

Authors:  Joaquín Gavilá; Mafalda Oliveira; Tomás Pascual; Jose Perez-Garcia; Xavier Gonzàlez; Jordi Canes; Laia Paré; Isabel Calvo; Eva Ciruelos; Montserrat Muñoz; Juan A Virizuela; Isabel Ruiz; Raquel Andrés; Antonia Perelló; Jerónimo Martínez; Serafín Morales; Mercedes Marín-Aguilera; Débora Martínez; Juan C Quero; Antonio Llombart-Cussac; Aleix Prat
Journal:  BMC Med       Date:  2019-01-09       Impact factor: 8.775

10.  6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Authors:  Helena M Earl; Louise Hiller; Anne-Laure Vallier; Shrushma Loi; Karen McAdam; Luke Hughes-Davies; Adrian N Harnett; Mei-Lin Ah-See; Richard Simcock; Daniel Rea; Sanjay Raj; Pamela Woodings; Mark Harries; Donna Howe; Kerry Raynes; Helen B Higgins; Maggie Wilcox; Chris Plummer; Janine Mansi; Ioannis Gounaris; Betania Mahler-Araujo; Elena Provenzano; Anita Chhabra; Jean E Abraham; Carlos Caldas; Peter S Hall; Christopher McCabe; Claire Hulme; David Miles; Andrew M Wardley; David A Cameron; Janet A Dunn
Journal:  Lancet       Date:  2019-06-06       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.